What considerations guide pharmacotherapy for alcohol use disorder in patients with hepatic disease?

• A. Acamprosate is renally excreted and generally preferred; naltrexone and disulfiram require caution with liver disease; monitor liver enzymes
• B. Naltrexone is always preferred in liver disease
• C. Disulfiram is completely safe in severe liver disease
• D. No special considerations; standard dosing applies

Answer: (C)

When liver disease is present, the safest and most practical approach to pharmacotherapy for alcohol use disorder is to favor medications that do not rely on hepatic metabolism or cause liver injury, and to monitor liver function closely if any agent is used. Acamprosate fits this approach because it is renally excreted and largely independent of the liver for its clearance, making it generally preferable when the liver is compromised. Its use typically does not require dose adjustment for mild hepatic impairment, and it avoids adding hepatic strain while supporting abstinence.

Naltrexone, on the other hand, is metabolized by the liver and has known potential to cause hepatotoxicity, especially at higher doses or in individuals with existing liver disease. Therefore it warrants caution and careful liver function monitoring, and it may be avoided or used with strict monitoring in significant hepatic impairment.

Disulfiram is associated with hepatotoxic risk and is contraindicated or used with extreme caution in patients with liver disease due to potential for serious liver injury. That makes it unsuitable as a first-line option in this population.

Thus, in hepatic disease, the general principle is to choose agents with minimal hepatic metabolism or toxicity (like acamprosate when appropriate) and to approach others with caution and liver monitoring, rather than applying standard dosing without regard to liver function.